Maxim Group upgraded Celsion (NASDAQ:CLSN) to “buy” from “hold” with a $7 price target after the company renegotiate outstanding warrants, raising $15.6-million.Read More
Maxim Group cut its price target for “buy-rated” Celsion (NYSE:CLSN) to $4 from $9. The stock was quoted at $1.22 Friday afternoon.
“While we are believers in Celsion’s ThermoDox product and platform, we recognize that pivotal Phase 3 data [from the OPTIMA study] will not arrive until late 2018,” writes analyst Jason McCarthy.Read More
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday.
Celsion has developed two cancer therapeutic platforms: LTSL for the delivery of chemotherapies and TheraPlas for the delivery of therapeutic DNA, RNA or proteins, both of which allow drugs to be delivered locally at high concentrations for greater therapeutic benefit and lower toxicity.Read More